ArticleThe international journal of cardiovascular imaging2017
Prognostic value of a faster, low-radiation myocardial perfusion SPECT protocol in a CZT camera.
Article in The international journal of cardiovascular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Long-Term Prognostic Value of Automated Measurements in Nuclear Cardiology: Comparisons with Expert Scoring.Medicina (Kaunas, Lithuania) · 2023Article
- Regional myocardial perfusion imaging in predicting vessel-related outcome: interplay between the perfusion results and angiographic findings.European journal of nuclear medicine and molecular imaging · 2022Article
- Is the CZT technology the future of nuclear cardiology?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Exploration of the efficacy of radiomics applied to left ventricular tomograms obtained from D-SPECT MPI for the auxiliary diagnosis of myocardial ischemia in CAD.The international journal of cardiovascular imaging · 2022Article
- Advanced technology in the risk stratification-based strategy: The way forward to keep going.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Prognostic value of myocardial perfusion imaging with D-SPECT camera in patients with ischemia and no obstructive coronary artery disease (INOCA).Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- The additional prognostic value of myocardial perfusion SPECT in patients with known coronary artery disease with high exercise capacity.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- The prognostic value of ultra low-dose thallium myocardial perfusion protocol using CZT SPECT.The international journal of cardiovascular imaging · 2019Article
- Cardiovascular imaging 2017 in the International Journal of Cardiovascular Imaging.The international journal of cardiovascular imaging · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine the prognostic value of a new, ultrafast, low dose myocardial perfusion SPECT (MPS) protocol in a cadmium-zinc telluride (CZT) camera. CZT cameras have introduced significant progress in MPS imaging, offering high-quality images despite lower doses and scan time. Yet, it is unknown if, with such protocol changes, the prognostic value of MPS is preserved. Patients had a 1-day 99 m-Tc-sestamibi protocol, starting with the rest (185-222 MBq) followed by stress (666-740 MBq). Acquisition times were 6 and 3 min, respectively. MPS were classified as normal or abnormal perfusion scans and summed scores of stress, rest, and difference (SSS, SRS and SDS), calculated. Patients were followed with 6-month phone calls. Hard events were defined as death or nonfatal myocardial infarction. Late revascularization was that occurring after 60 days of MPS. 2930 patients (age 64.0 ± 12.1 years, 53.3% male) were followed for 30.7 ± 7.5 months. Mean dosimetry was 6 mSv and mean total study time, 48 ± 13 min. The annual hard event and late revascularization rate were higher in patients with greater extension of defect and ischemia. SSS was higher in patients with hard events compared to those without events (2.6 ± 4.9 vs. 5.0 ± 6.3, p < 0.001), as well as the SDS (0.7 ± 1.9 vs. 1.7 ± 3.4, p < 0.00). The same was true for patients with or without late revascularization (SSS: 2.5 ± 4.7 vs. 6.6 ± 7.1; SDS: 0.6 ± 1.7 vs. 2.9 ± 3.8, p < 0.01). A new, faster, low-radiation, MPS protocol in a CZT camera maintain the ability to stratify patients with increased risk of events, showing that, in the presence of greater extension of defect or ischemia, patients presented higher rates of hard events and late revascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.